Should AV Marketers Treat Content Creators as Prosumers or Professionals?

 

Key Points:

  • 40% of people worldwide identify as content creators according to Shure and Futuresource.
  • 40 million people are creating audio-only content like podcasts or music.
  • Creators are looking for the right gear at the right price to support their growing passions; 65% expect to spend more time on their content in the next year.

Commentary:

AV marketers have been asking themselves, have there ever been this many content creators in the world? A convergence of different platforms, lower barriers to entry, and affordable high-powered gear is giving people an unrivaled opportunity to create audio, video, and interactive content, and the numbers reflect it. A recent Shure and Futuresource study found two in five people identify as content creators of “podcasts, music, streaming, and gaming,” with 40 million specifically creating audio-focused content.

The connection to gear bares out in the numbers, too. Close to half of creators surveyed invested in new audio equipment over the last year to improve the quality of their content, and for good reason, as 65% of respondents signaled an expected increase in their creator workload.

Besides an affordable price, what is motivating creators’ gear investments? And how are companies with a stake in supporting creators, whether through their platform or their equipment, supporting and capitalizing on this growth in the market? Daniel Litwin spoke with Laura Davidson, Market Development Manager at Shure Incorporated, explained how Shure’s partnerships with AV marketers and platforms like OBS Studio have kept the company’s ear to the ground on creators’ needs, and how that’s borne out in their product development.

Abridged Thoughts:

If you’re anything like two in five people in the world, you might find yourself identifying as a content creator. And if you’ve gone to record your podcast or live stream or game, you may have found yourself struggling with technology, whether it be audio, video, lighting or more. So, with this emerging trend of content creation, we’ve found that it’s an opportunity for Shure to provide thought leadership for those who are out there actively creating content and remove those barriers so that you can have the best experience when you’re ready to go live or hit record and take the technological barriers out of the way. So specifically, our Shure line of MOTIV™ microphones allow you to plug and play directly into your device or your computer so that you can get great sounding audio no matter where you are. There’s also a software element to this as well.

 

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More